Volume 10, Number 5—May 2004
Research
Clinical Manifestations, Laboratory Findings, and Treatment Outcomes of SARS Patients
Jann-Tay Wang*, Wang-Huei Sheng*, Chi-Tai Fang*, Yee-Chun Chen*, Jiun-Ling Wang*, Chong-Jen Yu*, Shan-Chwen Chang*
, and Pan-Chyr Yang*
, and Pan-Chyr Yang*
Table 1
Demographic data and initial clinical signs and symptoms of 76 patients with probable SARSa
| Data | No. of cases (%) |
|---|---|
| Sex |
|
| Male |
34 (44.7) |
| Female |
42 (55.3) |
| Age (y) (range, median) |
24–87 (46.5) |
| Underlying disease (no.) |
|
| Nonfatal |
62 (81.6) |
| No underlying disease |
52 (68.4) |
| Mild underlying disease |
10 (13.2) |
| Ultimately fatal |
3 (3.9) |
| Rapidly fatal |
11 (14.5) |
| Initial symptoms |
|
| Fever |
76 (100) |
| Cough |
47 (61.8) |
| Myalgia |
37 (48.7) |
| Dyspnea |
31 (40.8) |
| Diarrhea |
24 (31.6) |
| Rigor |
23 (30.3) |
| Headache |
14 (18.4) |
| Nausea |
9 (11.8) |
| Sore throat |
7 (9.2) |
| Vomiting |
3 (3.9) |
| Rhinorrhea | 2 (2.6) |
aSARS, severe acute respiratory syndrome.
Page created: February 22, 2011
Page updated: February 22, 2011
Page reviewed: February 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.